Investigation of the role of MMP3 -1171insA polymorphism in cutaneous malignant melanoma – a preliminary study

Figures & data

Figure 1. Agarose gel electrophoresis for genotyping for MMP3 -1171insA polymorphism.

Table 1. Genotype and allele distribution of MMP3 -1171insA in the groups of patients with coetaneous melanoma and controls and estimated ORs.

	Melanoma Pts.		Controls
	n		n
MMP3 -1171insA (5A>6A)	n = 24	Frequency	n = 172	Frequency	OR (95% CI), p-value
Genotype frequency (crude analysis)
Co-dominant model
5А/5А	4	0.154	36	0.209	1.0 (referent)
5А/6А	16	0.615	80	0.465	1.80 (0.59–5.48) p = 0.429
6А/6А	6	0.231	56	0.326	0.96 (0.27–3.41) p = 0.957
Dominant model
5А/5А	4	0.154	36	0.209	1.0 (referent)
(5A/6A + 6А/6А)	22	0.846	136	0.791	1.46 (0.49–4.28), p = 0.512
Recessive model
5А/5А + 5А/6А	20	0.769	116	0.674	1 (referent)
6А/6А	6	0.231	56	0.326	0.62 (0.24–1.59), p = 0.331
Allele frequency
-1171 5А (high-producing allele)	24	0.462	152	0.442	1.0 (referent)
-1171 6А (low-producing allele)	28	0.538	192	0.558	0.92 (0.52–1.65), p = 0.790

Figure 2. Distribution genotypes and alleles of MMP3 -1171insA polymorphism in patients with coetaneous melanoma and in control individuals.

Figure 3. Disease-free survival of the patients with coetaneous melanoma according the MMP3 -1171insA genotypes: (A) patients are divided in three groups – carriers of 5A/5A, 5A/6A and 6A/6A genotypes; (B) patients are divided into two groups: carriers of 5A allele genotypes (5A/5AC5A/6A) and carriers of 6A/6A genotype.

Figure 4. Overall survival of the patients with coetaneous melanoma according the MMP3 -1171insA genotypes: (A) patients are divided in three groups – carriers of 5A/5A, 5A/6A and 6A/6A genotypes; (B) patients are divided into two groups: carriers of 5A allele genotype (5A/5AC5A/6A) and carriers of 6A/6A genotype.